Authors:
Berta M. Geller, Karla Kerlikowske, Patricia A. Carney, Linn A. Abraham, Bonnie C. Yankaskas, Stephen H. Taplin, Rachel Ballard-Barbash, Mark B. Dignan, Robert Rosenberg, Nicole Urban, William E. Barlow
Berta M. Geller Karla Kerlikowske Patricia A. Carney Linn A. Abraham Bonnie C. Yankaskas Stephen H. Taplin Rachel Ballard-Barbash Mark B. Dignan Robert Rosenberg Nicole Urban William E. Barlow
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.